Can Sanofi And GSK Catch Up In mRNA Vaccines?
Pfizer And Moderna Have Head Start
GSK and Sanofi have little chance of making a big impact in COVID-19 vaccines, but hope to establish themselves in the technology in key markets such as flu.
You may also be interested in...
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.
In this week's podcast edition of Five Must-Know Things: senior level changes at Lilly; mRNA COVID vaccines and booster shots; GSK and Sanofi deal with a changed vaccines landscape; a look ahead at new drugs for hematological malignancies; and a huge fundraising in China for an mRNA specialist.